Researchers have made a discovery linking chromosomal instability to cancer metastasis through chronic inflammation, a first in identifying a widespread genomic driver of metastasis.
The US Food and Drug Administration approved lutetium Lu 177 dotatate (Lutathera) for the treatment of somatostatin receptor–positive gastroenteropancreatic neuroendocrine tumors in adults.
Immunochemotherapy should remain the standard induction approach for patients with high-risk follicular lymphoma.
Long-term follow-up of a large phase III study showed that chemohormonal therapy involving docetaxel added to androgen deprivation therapy (ADT) prolongs overall survival over ADT alone in metastatic hormone-sensitive prostate cancer patients with high-volume disease.
Patients with head and neck cancer who had depressive symptoms at the time of treatment planning had worse overall 2-year mortality.
Investigators found a methylation-independent loss of MYO5B expression in CRC that matched disease progression, which indicates that the use of MYO5B alone or in combination with its adapter protein RAB8A is a prognostic marker for the disease.
Using a super computer, a team at Brown University has created a model of sickle cell anemia, devising a method that could help researchers assess and evaluate treatments to combat sickle cell disease.
A new study demonstrates that it is possible to vaccinate patients with MDS against a decitabine-induced antigen and that the level of induced expression is sufficient to trigger cytotoxicity in patient-derived vaccine-induced T cells.
Adding palbociclib to letrozole offers similar health-related quality of life and better pain scores in postmenopausal women with estrogen receptor–positive/HER2-negative metastatic breast cancer, compared to letrozole alone, according to an analysis of the PALOMA-2 trial.
Venetoclax had promising clinical activity in patients with relapsed or refractory chronic lymphocytic leukemia previously treated with idelalisib.